anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months. Red clover capsules contained 40 mg of standardized red clover isoflavones in each capsule \[genistein (1 mg), daidzein (1 mg), biochanin A (23 mg) and biochanin B (formononetin, 15 mg)\].
BACKGROUND/AIM: Oral cancer (OC) is the leading cause of fatalities in Pakistan among males due to inadequate oral hygiene and chewing habits. However, genetic susceptibility patterns also play a critical role in disease progression. Since the frequency of Resistin (RETN) SNP (Single nucleotide polymorphism) rs3219175 is unknown; there is a requirement for early diagnosis of the OC. Therefore, the current study aims to determine the frequency of targeted SNP and develop a safe, simple, and fast alternative technique for better treatment using a real-time PCR assay with HRM (high-resolution melting curve) analysis.
MATERIALS AND METHODS: A case-control study was conducted on 35 Oral squamous cell carcinomas (OSCC) diagnosed patients and 35 healthy individuals. HRM and RT-PCR results were analysed by the bioinformatics analyses.
RESULTS: The frequency of RETN SNP rs3219175 genotypes GG and GA in male patients was 16 (46 %) and 5 (14 %) respectively and in females 8 (23 %) and 6 (17 %) respectively. The chi-square test of independence consummated the assessment between males and females in both control and patients. The relation between these variables was significant (p < 0.05). The interaction network of String 8.3 demonstrates strong interactions at a high confidence score, which helps to characterize functional disorders that may be a causative factor for oral pathology. Reactome and KEGG data were acquired to rule out the pathway involvement of the targeted gene. MuPIT software was used to identify the 3D structure or RETN and their expected mutation effect.
CONCLUSION: This study provides baseline data regarding the frequency of RETN SNP rs3219175 among the Pakistani population. For further clarification of their stage in cancer emergence and growth, large-scale studies must be conducted. This study might be helpful in the precision medicine approach and provide better therapeutic for OSCC patients.
Drugs which may enhance the neuromuscular blocking action of succinylcholine include: promazine, oxytocin, aprotinin, certain nonpenicillin antibiotics, quinidine, ß-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, diethylether, isoflurane, desflurane, metoclopramide, and terbutaline. The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase (see PRECAUTIONS). 

If other neuromuscular blocking agents are to be used during the same procedure, the possibility of a synergistic or antagonistic effect should be considered.

Carcinogenesis, Mutagenesis, Impairment of Fertility   
There have been no long-term studies performed in animals to evaluate carcinogenic potential of succinylcholine. Genetic toxicology studies have not been completed to evaluate the genotoxic potential of succinylcholine. There are no studies to evaluate the potential impact of succinylcholine on fertility.
Knee osteoarthritis (KOA), also known as degenerative joint disease, is the most common type of arthritis diagnosed. KOA is typically the result of wear and tear and progressive loss of articular cartilage. The prevalence of the Knee osteoarthritis will continue to increase as life expectancy and obesity rises. Osteoarthritis is typically a progressive disease that may eventually lead to disability. The intensity of the clinical symptoms may vary from each individual. However, they typically become more severe, more frequent, and more debilitating over time.The intensity of the clinical symptoms may vary from each individual. However, they typically become more severe, more frequent, and more debilitating over time.

The rate of progression also varies for each individual. Common clinical symptoms include knee pain that is gradual in onset and worse with activity, knee stiffness and swelling, pain after prolonged sitting or resting, and pain that worsens over time. Treatment for knee osteoarthritis begins with conservative methods and progresses to surgical treatment options when conservative treatment fails. While medications can help slow the progression of RA and other inflammatory conditions, no proven disease-modifying agents for the treatment of knee osteoarthritis currently exist. Among the more innovative, experimental therapies, mesenchymal stromal cells (MSCs) are proposed as a novel therapy with potential in treatment of KOA.
A solution for managing access to exercise equipment in a fitness facility is provided. A planned exercise routine for a user, which includes data corresponding to a plurality of exercises desired to be performed by the user at the fitness facility is used for providing location information for presentation to the user. Each exercise can require use of an exercise apparatus. The exercise can be mapped to at least one exercise apparatus located at the fitness facility. A target exercise apparatus can be identified from the mapped exercise apparatus(es). Location information for one or more of the target exercise apparatuses can be provided for presentation to the user.
The Move intervention is a 24-week evidence-based program based on social cognitive theory. It was originally developed for midlife women and successfully maintained increased physical activity. It has since been tailored for older women with CVD to prevent or delay cognitive decline, and includes: (1) education on the importance of lifestyle physical activity for brain health, (2) increasing lifestyle physical activity while considering CVD, and (3) including a goal for increasing Fitbit "active" minutes (≥ 3 METs or moderate-intensity physical activity) to ensure participants are obtaining the beneficial aerobic fitness effects during periods of lifestyle physical activity. Core elements include a personal lifestyle physical activity goal and five group meetings.
Doses of bortezomib given is 1.3 mg/m2 weekly x 4 weeks given every 3 month x 8 cycles. Doses of RITUXAN given is 375 mg/m2 give weekly x 4 weeks given every 6 month for 4 cycles.
Oral formulation of particles made of an agglomeration of a plurality of seed granules or a single seed granule both surrounded by three layers and an outer gel coating. The seed granules are made of calcium carbonate with microscopic fissures. Disposed inside the fissures and in the interstitial spaces of the agglomerate seed granules are microscopic particles of alkali metal salts and other ions. Coating the agglomerate or single seed granules is an alkaline-resistant first layer made of microcrystalline cellulose and croscarmellose sodium that binds and protects the surrounding second layer. Surrounding the first layer is a second layer comprising a mixture of a flavonoid and polysaccharide or polypeptide binder or polymer gel. Surrounding the second layer is a third layer made of alkaline earth metal salt particles holding alkali metal hydroxide ions within a polysaccharide or polymer gel. Surrounding the third layer is at least one outer gel layer. The fourth and third layers dissolve in a low pH environment and release the fat soluble antioxidant and ions in the seed granule fissures.
Patients were interviewed twice, at baseline and at the 3rd month. All forms were applied to the patients in the control group at baseline. In the 3rd month, the same forms were applied to the untrained patients in the control group.
The invention belongs to the technical field of biological medicines, and particularly relates to application of SPC25 in glioma diagnosis, treatment and prognosis. A biomarker for glioma, said marker being an SPC25 gene/protein. Use of SPC25 gene/protein in the preparation of a kit for the diagnosis and/or prognosis of glioma. Use of an inhibitor of the SPC25 gene/protein for the manufacture of a medicament for the treatment of glioma, said inhibitor being capable of inhibiting the function of the SPC25 gene/protein. Experiments prove that the expression of the SPC25 gene and protein in glioma in vivo is obviously up-regulated compared with normal brain tissues, so that SPC25 is expected to be an auxiliary diagnostic marker of tumor. The invention provides a new theoretical basis and a new target for glioma treatment and also provides a new auxiliary diagnosis and prognosis diagnosis method for glioma.
Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
Risk Summary

Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breastfeeding females. This reduction can occur at any time but is less likely to occur once breastfeeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breastfeeding. (see DOSAGE AND ADMINISTRATION). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for MARLISSA® (levonorgestrel and ethinyl estradiol tablets) and any potential adverse effects on the breastfed child from MARLISSA® or from the underlying maternal condition.
The present disclosure relates to a method for determining node metrics based on node field-value pairs and electronic activities. The method includes identifying a first node profile. The method includes identifying a plurality of electronic activities associated with the first node profile. The method includes identifying a first group of node profiles of a first category with a predetermined event. The method includes selecting a second group of node profiles. The method includes parsing the plurality of electronic activities to identify creation timestamps and participant characteristics of the electronic activities. The method includes generating an input array based on the timestamps and the participant characteristics. The method includes generating, for each of the second group of node profiles, a respective array. The method includes determining a probability score indicating a likelihood that the node profile belongs to the first category.
Magnesium (Mg) is a crucial element for cardiovascular system and its deficiency results in a variety of cardiac arrhythmias. The aim of this study is to determine the effect of oral Mg supplementation on the frequency of ventricular extrasystoles (VES) in children. Magnesium supplementation was given to 42 children who had VES without structural heart disease. Clinical, electrocardiographic, and Holter monitoring studies were reviewed. The mean baseline 24 h VES burden on Holter monitoring was 10.26% ± 4.13% and it was decreased to 6.62% ± 3.88% after. There was no significant difference between the pre-treatment serum Mg levels and the decrease in the frequency of VES. In conclusion, oral Mg therapy was found to be effective at suppressing VES in children regardless of serum Mg levels. Large and randomized studies are needed to demonstrate the effect of magnesium on VES suppression.
The present invention relates to a channel soothing and vessel dredging pill for treating the protrusion of lumbar intervertebral discs, which is characterized in that the channel soothing and vessel dredging pill for treating protrusion of lumbar intervertebral discs is prepared from 120 to 125 portions of ground beetle, 119 to 124 portions of Chinese angelica root, 90 to 95 portions of earthworm, 89 to 94 portions of hiraute shiny bugleweed herb, 90 to 95 portions of pangolin scale, 90 to 95 portions of tree peony bark, 74 to 78 portions of astragalus root, 75 to 80 portions of prepared rehmannia root, 75 to 80 portions of black-tail snake, 75 to 80 portions of pubescent angelica root, 75 to 80 portions of scorpion and 75 to 80 portions of Radix Cyathulae as raw materials according to portions by weight. According to a traditional Chinese medicine theory, through the analysis of medical theory and medical property of various medicines, the present invention is developed through long time test and clinical observation. The medicine has the functions of nourishing qi and blood and activating blood circulation to dissipate blood stasis and has good effect on treating the protrusion of intervertebral discs. The present invention has the advantages of outstanding curative effects and low expense of treatment. The present invention has another advantage of non-operative treatment. The present invention is a medicine for oral administration, and patients do not have pain in the process of treatment.
The invention relates to a levo-ornidazole sodium chloride injection and a preparation process thereof, wherein the levo-ornidazole sodium chloride injection is prepared from levo-ornidazole, 0.1M hydrochloric acid, sodium chloride and water for injection. The preparation process comprises adding 0.1M hydrochloric acid, sodium chloride, and levoornidazole into water for injection, stirring, and dissolving. Adsorbing with activated carbon, removing carbon, adding the medicinal liquid into diluting tank, adjusting pH, adding water for injection to full volume, inspecting intermediate, and packaging. The levoornidazole sodium chloride injection has better treatment effect. The invention provides a new production and preparation process of a levoornidazole sodium chloride injection. The production and preparation process has better sterilization effect.
AIMS: Wearable cardioverter-defibrillators (WCDs) are indicated in patients at risk of sudden cardiac arrest who are not immediate candidates for implantable defibrillator therapy. Limitations of existing WCDs include poor compliance and high false alarm rates. The Jewel is a novel patch-WCD (P-WCD) that addresses these limitations with an adhesive-based design for near-continuous wear and a machine learning algorithm designed to minimize inappropriate detections. This was a first-in-human study of the Jewel P-WCD conducted in an electrophysiology (EP) lab to determine the safety and effectiveness of the device in terminating ventricular tachycardia/ventricular fibrillation (VT/VF) with a single shock. The aim was to evaluate the safety and effectiveness of terminating VT/VF with a single shock using the Jewel P-WCD.
METHODS AND RESULTS: This was a first-in-human, prospective, single-arm, single-centre study in patients scheduled for an EP procedure in which VT/VF was expected to either spontaneously occur or be induced. The Jewel P-WCD was placed on consented patients; upon confirmation of VT/VF, a single shock (150 J) was delivered via the device. A group sequential design and Pocock alpha spending function was used to measure the observed proportion of successful VT/VF single-shock terminations. The endpoint was achieved if the lower confidence limit exceeded the performance goal of 62%, using a one-sided lower 97.4% exact confidence bound. Of 18 eligible subjects, 16 (88.9%, 97.4% confidence bound: 65.4%) were successfully defibrillated with a single shock, exceeding the primary endpoint performance goal with no adverse events.
CONCLUSION: This first-in-human evaluation of the Jewel P-WCD demonstrated the safety and effectiveness of terminating VT/VF.
CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov/; Unique identifier: NCT05490459.
PROBLEM TO BE SOLVED: To obtain the subject unit such as tablet or capsule, capable of storing in dry state and reducing the amount of administration of active ingredient(s), by including a pharmaceutical carrier containing tibolone and a water-insoluble starch product. SOLUTION: This unit is obtained by including 0.1-10 wt.% tibolone and a pharmaceutical carrier containing 10-100 wt.% starch. The starch includes potato starch and corn starch. It is preferable that the weight ratio of tibolone and that of starch to the carrier are each 0.02 wt.% or lower. Up to 5 wt.% of a stabilizer selected from antioxidants, chelating agents, and mixtures thereof, can also be formulated. The administration unit is manufactured by mixing part of a desired composition of a carrier, tibolone, and, if necessary, a stabilizing agent, and sieving the resultant mixture, admixing the remainder of the carrier, followed by admixing a lubricant. Stability of tibolone is enhanced by increasing the amount of starch to be used in the carrier.
The invention relates to a lovastatin and niacin sustained-release preparation. Each tablet contains 500mg niacin and 20mg lovastatin according to weight proportion; matrix tablets preparation technology is adopted to prepare the niacin as a sustained-release share and the lovastatin as a quick-release share; and the two shares are compressed to be a compound sustained release tablet. The compound preparation is mainly used for treating hypercholesterolemia, and the HDL is increased by 41%, the LDL is decreased by 45%, and the triglyceride is decreased by 42% after one year treatment. The development of the sustained release tablet can effectively control the release of medicament so that the medicament release rate can reach a preset value, the blood concentration is smoother and the fluctuation phenomenon lead by common preparation is decreased. The invention ensures that not only the toxic side effect caused by the common preparation is reduced, and the deficient of frequent medicine taking is overcame but also the situations of missing or forgetting are avoided and the use is convenient for a patient. When the two are jointly used, synergic action is obtained. The invention has simple preparation process and is suitable for industrial production.
BACKGROUND: The Internet is a widely used source of health information, yet the accuracy of online information can be low. This is the case for low back pain (LBP), where much of the information about LBP treatment is poor.
METHODS: This research conducted a content analysis to explore what pain treatments for LBP are presented to the public on websites of Australian pain clinics listed in the PainAustralia National Pain Services Directory. Websites providing information relevant to the treatment of LBP were included. Details of the treatments for LBP offered by each pain service were extracted.
RESULTS: In total, 173 pain services were included, with these services linking to 100 unique websites. Services were predominantly under private ownership and located in urban areas, with limited services in non-urban locations. Websites provided detail on a median of six (IQR 3-8) treatments, with detail on a higher number of treatments provided by services in the private sector. Physical, psychological and educational treatments were offered by the majority of pain services, whereas surgical and workplace-focused treatments were offered by relatively few services. Most services provided details on multidisciplinary care; however, interdisciplinary, coordinated care characterised by case-conferencing was infrequently mentioned.
CONCLUSIONS: Most websites provided details on treatments that were largely in-line with recommended care for LBP, but some were not, especially in private clinics. However, whether the information provided online is a true reflection of the services offered in clinics remains to be investigated.
OBJECTIVE: Megestrol acetate (MA) is used to manage anorexia and cachexia in patients with advanced cancer. This study investigated the prescription patterns of MA in patients with metastatic gastric cancer, as well as evaluated its impact on survival outcomes and the incidence of venous thromboembolism (VTE).
METHODS: A Health Insurance Review and Assessment (HIRA) service database was used to investigate differences in baseline characteristics, survival, and the incidence of VTE according to MA prescription patterns (i.e., prescription vs. no prescription) in patients diagnosed with metastatic gastric cancer from July 2014 to December 2015.
RESULTS: A total of 1938 patients were included in this study. In total, 65% of the patients were prescribed MA. Older age, treatment in tertiary hospitals, and palliative chemotherapy were statistically significant predictive factors for MA prescription. Continuous prescription of MA was observed in 37% of patients. There was no statistically significant difference in survival between the MA and non-MA prescription groups on multivariate analysis. Among the 1427 patients included in the analysis for VTE incidence, 4.3% and 2.9% were diagnosed with VTE during the follow-up period in the MA and non-MA prescription groups, respectively. However, there was no statistically significant difference in VTE diagnosis between the groups on multivariate analysis.
CONCLUSION: MA is commonly prescribed for metastatic gastric cancer, especially in elderly patients and those undergoing palliative chemotherapy, without significantly affecting survival or VTE risk.
The invention provides a preparation method of a multifunctional intestinal tract diagnosis and treatment preparation and a product thereof, wherein the multifunctional intestinal tract diagnosis and treatment preparation product simultaneously has a multifunctional probe for PET imaging, ultrasonic imaging and photothermal therapy, can simultaneously meet the requirements of accurate tumor positioning and high flexibilitySensitive long-period imaging is carried out, and the targeting imaging efficiency of the probe to the tumor is improved. Macrophages are used as a drug carrier 'reservoir'. The enrichment of the carrier at the tumor part is enhanced through the transfer effect of macrophage, and the chitosan can be effectively adsorbed on the surface of intestinal mucosa. 18 Class F ribozymes act as imaging agents for PET. The tumor position and the metastasis are determined through PET imaging, and the accurate positioning of the whole tumor is realized. Fluorocarbon compounds are used as ultrasound contrast agents. The diagnostic capability of local tumors is improved through ultrasonic imaging. The gold nanorods have photothermal effect and have the effect of treating tumor parts.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to oncology, and can be used within integrated treatment of locally advanced clay pipe cancer. That is ensured by blood sampling in the amount 200-250 ml from the median cubital vein, centrifugation and plasma separation in the amount 10 ml in 9 syringes of 20 ml. Plasma containers are placed in a freezing chamber, and the rest cell suspension is added with 150 ml of physiologic saline and reinfused intravenously drop-by-drop. On the following day, the lingual artery is catheterised to introduce a mixture incubated at temperature 37 C for 30 minutes and containing 10 ml of autoplasma and 30 mg of methotrexate in one syringe and 500 mg of 5-fluorouracil and 10 ml of autoplasma in the second syringe. Such mixture is introduced daily during 4 days. 3 weeks later, a surgical removal the tumour follows with a bed of the removed tumour being injected all around during the operation with the mixture of 30 mg methotrexate and 10 ml of autoplasma incubated similarly that is followed with operative wound closure. ^ EFFECT: method allows higher clinical effectiveness in the case patients that is ensured by chemopreparations depot in a tumour lesion. ^ 1 ex